Intrauterine Growth Restriction Synonyms: IUGR, fetal growth restriction, FGR Intrauterine growth restriction (IUGR) is a condition where a baby's growth slows or ceases when it is in the uterus. It is part of a wider group - small for gestational age (SGA) fetuses - which includes fetuses that have failed to achieve their growth potential and fetuses that are constitutionally small. Approximately 50-70% of fetuses with a birth weight below the tenth centile for gestational age are constitutionally small. The lower the centile for defining SGA, the greater the likelihood of IUGR. On the other hand, a fetus with growth restriction may not be SGA.[1] There is increased risk of: Intrapartum fetal distressIntrapartum asphyxiaPostnatal hypoglycaemia or hypocalcaemia neonatal complicationsImpaired neurodevelopmentMeconium aspirationIntrauterine deathPossibly type 2 (non insulin-dependent) diabetes and hypertension in adult life Major risk factors Minor risk factors There may be racial differences. Other investigations include:[1]
TheLancet.com - Home Page Postnatal Care (Puerperium) oPatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets. The puerperium covers the 6-week period following birth, during which time the various changes that occurred during pregnancy revert to the non-pregnant state. Physiological changes during this time include: The cardiovascular system reverts to normal during the first 2 weeks. This is based on NICE guidance.[1] This is covered in detail in our separate article Postpartum Contraception. Contraception is not necessary in the 21 days after childbirth.Methods that are suitable choices for breast-feeding women include the lactation-amenorrhoea method, barrier methods, intrauterine devices (including the levonorgestrel-releasing intrauterine system), the progestogen-only pill, injectable progesterone contraceptives, the etonogestrel implant and sterilisation.
ACP - Medical Oncologists Neonatal Jaundice Jaundice is clinically detectable in the newborn when the serum bilirubin levels are greater than 85 μmol/L. This occurs in approximately 60% of term infants and 80% of preterm infants. Hyperbilirubinaemia is either unconjugated (which is potentially toxic but may be physiological or pathological) or conjugated (not toxic but always pathological). Without treatment, high levels of unconjugated bilirubin may lead to kernicterus. Approximately 60% of term and 80% of preterm babies develop jaundice in the first week of life, and about 10% of breast-fed babies are still jaundiced at 1 month of age.[1] Risk factors The risk of developing significant neonatal jaundice is increased in: Low birth weight: premature and small for dates.Breast-fed babies.A previous sibling with neonatal jaundice requiring phototherapy.Visible jaundice in the first 24 hours.Infants of mothers who have diabetes.Male infants.East Asians.Populations living at high altitudes. Prolonged jaundice[1]
The Lancet Oncology : Volume 12, Number 9, 1 September 2011 Challenges to effective cancer control in China, India, and Russia Paul E Goss, Kathrin Strasser-Weippl, Brittany L Lee-Bychkovsky, Lei Fan, Junjie Li, Yanin Chavarri-Guerra, Pedro E R Liedke, C S Pramesh, Tanja Badovinac-Crnjevic, Yuri Sheikine, Zhu Chen, You-lin Qiao, Zhiming Shao, Yi-Long Wu, Daiming Fan, Louis W C Chow, Jun Wang, Qiong Zhang, Shiying Yu, Gordon Shen, Jie He, Arnie Purushotham, Richard Sullivan, Rajendra Badwe, Shripad D Banavali, Reena Nair, Lalit Kumar, Purvish Parikh, Somasundarum Subramanian, Pankaj Chaturvedi, Subramania Iyer, Surendra Srinivas Shastri, Raghunadhrao Digumarti, Enrique Soto-Perez-de-Celis, Dauren Adilbay, Vladimir Semiglazov, Sergey Orlov, Dilyara Kaidarova, Ilya Tsimafeyeu, Sergei Tatishchev, Kirill D Danishevskiy, Marc Hurlbert, Caroline Vail, Jessica St Louis, Arlene Chan Cancer is one of the major non-communicable diseases posing a threat to world health.
Postnatal care Fast, easy summary view of NICE guidance on 'postnatal care' The NICE clinical guideline on postnatal care covers the core care that every healthy woman and healthy baby should be offered during the first 6-8 weeks after the birth. Although for most women and babies the postnatal period is uncomplicated, care during this period needs to address any deviation from expected recovery after birth. This guideline gives advice on when additional care may be needed. Responsibility for undertaking a review of this guidance at the designated review date has passed to the National Clinical Guidelines Centre for Acute and Chronic Conditions (NCGCACC). Other information CG37 Postnatal care: NICE guideline (web format) NICE Pathways This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products. Visit the NICE Pathway: postnatal care Background information New NICE guidelines on postnatal care will give babies best start in life Guideline formats Patient
BMJ Best Practice Hi You are already registered. Please log in with your email & password. Congratulations! You have successfully created a personal account and can now track your CME / CPD activities and access the mobile app. Subscription complete Congratulations! Registration complete You have now registered and can access BMJ Best Practice for free at any time by logging in with the email and password you provided. In the spotlight Please log in Or log in via:
Your Baby, Jaundice and Phototherapy Your Baby, Jaundice, and Phototherapy What is Jaundice? Jaundice is a common, temporary. and usually harmless condition in newborn infants. Jaundice occurs when there is a build-up of a naturally occurring substance in the blood called bilirubin . What are the Causes of Jaundice? Jaundice can be caused by several different problems: Physiological jaundice: This is the most common cause of newborn jaundice and occurs in more than 50% of babies. What is the Treatment? High levels of bilirubin can occur in the blood called hyperbilirubinemia. What is Phototherapy? Some “normal” jaundice will disappear within a week or two without treatment. Phototherapy (light treatment) is the process of using light to eliminate bilirubin in the blood. For over 30 years, phototherapy treatment in the hospital has been provided by a row of lights or a spotlight suspended at a distance form a baby. Are there Side Effects of Using Phototherapy? What is the BiliBlanket? Can my baby sleep on a biliblanket? Yes.
American Society of Hematology Blood Basics Descriptions of the four main components of blood and the function of each within the body Blood Disorders Information on common blood disorders such as anemia, bleeding disorders including hemophilia, blood clots, and blood cancers Premature infant: MedlinePlus Medical Encyclopedia A premature infant is a baby born before 37 completed weeks of gestation (more than 3 weeks before the "due date"). Causes At birth, a baby is classified as one of the following: Premature (less than 37 weeks gestation)Full term (37 to 42 weeks gestation)Post term (born after 42 weeks gestation) If a woman goes into labor before 37 weeks, it is called preterm labor. "Late preterm" babies who are born between 35 and 37 weeks gestation may not look premature. Health conditions in the mother, such as diabetes, heart disease, and kidney disease, may contribute to preterm labor. Different pregnancy-related problems increase the risk of preterm labor or early delivery: Other factors that increase the risk for preterm labor and a premature delivery include: Age of the mother (mothers who are younger than 16 or older than 35)Being African-AmericanLack of prenatal careLow socioeconomic statusUse of tobacco, cocaine, or amphetamines Symptoms Exams and Tests Treatment If the infant has breathing problems:
Bliss - for babies born too soon, too small, too sick Duchenne's Muscular Dystrophy The muscular dystrophies are a group of inherited disorders characterised by progressive muscle wasting and weakness, of which Duchenne muscular dystrophy (DMD) is the most common. DMD is an X-linked recessive condition which presents in early childhood and inevitably progresses. Some carriers also have symptoms. New mutations are common in DMD; this means that female relatives of a child with DMD are not necessarily carriers of the gene.[1] DMD affects about 1 in 3,500 newborn males.[2] DMD is caused by abnormalities of the dystrophin gene, which is responsible for a cytoskeletal protein named dystrophin, located in muscle fibres. There is progressive proximal muscular dystrophy with characteristic pseudohypertrophy of the calves. Non-locomotor presenting symptoms: Patients with suspected DMD The initial investigation is serum CK: In DMD the CK level is very high (10-100 x normal from birth).A normal CK at presentation excludes DMD. Possible carriers of the gene Management in later stages